This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Our long-term goal is to elucidate the impact of the Mdm2-p53 pathway in vivo on tumor development as a necessary prerequisite to the development of therapeutic protocols for attenuating cancer. p53 functions as a tumor suppressor and exerts this function by activating numerous downstream targets such as p21, BAX, PUMA, GADD45 as a transcription factor1. Mdm2 is a major inhibitor of p53 through physical binding and induction of p53 degradation2. The p53 gene is mutated in more than 50% of tumors, and Mdm2 is highly expressed in a variety of tumors, stressing the importance of the Mdm2-p53 pathway in tumor development 3-6. It should be noted that a significant number of tumors have wild-type p53 with Mdm2 over-expression. Interestingly, some patients with tumors in which p53 gene is mutated and Mdm2 is over-expressed are known to have a poorer prognosis, compared to patients with mutant p53 alone in tumors7, 8. These results suggest that Mdm2 also has p53-independent roles in tumor development. Recently, Mdm2 is found to inhibitory interact with other tumor suppressors such as Rb, PML, and p73, which may contribute to p53-independent roles of Mdm2 in tumor development9-15. One can assume that any proteins that affect Mdm2 function may have an impact on tumor development. Mdm2 Binding Protein (MTBP) was isolated by Boyd MT et al.16 using the yeast two hybrid system with Mdm2 as bait. Over-expression of MTBP causes G1 arrest of cell cycle, but the effect is nullified by simultaneous over-expression of Mdm2. Our working hypothesis is that MTBP plays a critical role in tumor development and metastasis. This hypothesis is based on our preliminary results using a conventional mtbp knockout mouse in which we observed that (1) 30% of mtbp heterozygous mice spontaneously developed tumors within 22 months, and (2) doubly heterozygous knockout mice for mtbp and p53 developed metastatic osteosarcomas. Based on these observations, the focus of this proposal is on the roles of MTBP in osteosarcoma metastasis and the functional characterization of this protein.
The specific aims are designed to provide a comprehensive assessment of novel functions of MTBP, especially in osteosarcoma metastasis.
Aim 1. To characterize osteosarcomas induced by loss of mtbp.
Aim 2. To generate and characterize mice with conditional mtbp and/or p53 knockout alleles, specifically in osteoblasts.
Aim 3. To isolate MTBP interacting proteins.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR020152-08
Application #
8360720
Study Section
Special Emphasis Panel (ZRR1-RI-B (01))
Project Start
2011-08-01
Project End
2012-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
8
Fiscal Year
2011
Total Cost
$223,456
Indirect Cost
Name
Tulane University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
053785812
City
New Orleans
State
LA
Country
United States
Zip Code
70118
Wu, Victor J; Pang, Darren; Tang, Wendell W et al. (2017) Obesity, age, ethnicity, and clinical features of prostate cancer patients. Am J Clin Exp Urol 5:1-9
Zhang, Q; Liu, S; Parajuli, K R et al. (2017) Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene 36:687-699
Gopalakrishnan, Anusha M; Aly, Ahmed S I; Aravind, L et al. (2017) Multifunctional Involvement of a C2H2 Zinc Finger Protein (PbZfp) in Malaria Transmission, Histone Modification, and Susceptibility to DNA Damage Response. MBio 8:
Liu, Yao-Zhong; Zhang, Lei; Roy-Engel, Astrid M et al. (2017) Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells. Gene 602:16-23
Yang, Lingyun; Huang, Feng; Mei, Jiandong et al. (2017) Posttranscriptional Control of PD-L1 Expression by 17?-Estradiol via PI3K/Akt Signaling Pathway in ER?-Positive Cancer Cell Lines. Int J Gynecol Cancer 27:196-205
Wang, Xun; Yang, Lingyun; Huang, Feng et al. (2017) Inflammatory cytokines IL-17 and TNF-? up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett 184:7-14
Ma, Lin; Li, Jingwu; Nie, Qiang et al. (2017) Organoid culture of human prostate cancer cell lines LNCaP and C4-2B. Am J Clin Exp Urol 5:25-33
Servant, Geraldine; Streva, Vincent A; Derbes, Rebecca S et al. (2017) The Nucleotide Excision Repair Pathway Limits L1 Retrotransposition. Genetics 205:139-153
Martin, Elizabeth C; Conger, Adrienne K; Yan, Thomas J et al. (2017) MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. FEBS Lett 591:382-392
Zhang, Qiuyang; Liu, Sen; Ge, Dongxia et al. (2017) Targeting Th17-IL-17 Pathway in Prevention of Micro-Invasive Prostate Cancer in a Mouse Model. Prostate 77:888-899

Showing the most recent 10 out of 154 publications